

Technical Information

M65® ELISA (PEVIVA®)

Apoptosis + Necrosis.

Human intermediate filament protein cytokeratin 18 (K18).

Released from human epithelial cells.

CE

Cat. No.:	10020
Tests:	96
Method:	ELISA
Range:	125 - 2000 U/L (The Units measured by the M65® ELISA are defined against a synthetic standard. 1 U/L = 1.24 pM.)
LLOD:	25 U/L
LLOQ:	67 U/L
Incubation time:	2 hours 20 minutes
Sample volume:	25 µl
Sample type:	serum, plasma (EDTA, Heparin, Citrate) and cell (epithelial cell)
Sample preparation:	Store samples at 2 – 8 °C up to 4 hours. For longer periods, store samples frozen at -20 ° or lower. Samples can be freeze-thawed without loss of activity it is recommended that repeated freeze thawing should be avoided.
Reference values:	Cut-off > 400 U/L - 222 normal subjects, 95 th percentile 413 U/L
Species:	Human, primates, bovine.
Specificity:	The assay uses two monoclonal antibodies directed to epitopes in the 284 – 396 region of the K18 protein. Soluble full length K18 as well as K18 fragments and protein complexes that expose these epitopes will be detected by the assay.

Intended Use:

Quantitative measurement of total soluble cytokeratin 18 (K18) released from dead cells (necrotic and apoptotic). The cells or tissues should be of human epithelial origin (e.g. kidney, gut, colon, lung or liver) expressing K18.

The M65® ELISA can be combined with the M30-Apoptosense® ELISA (PEVIVA Prod. No. 10010) for determination of cell death mode (apoptosis versus necrosis). Death mode can be determined in vitro and in serum from cancer patients (Kramer *et al.*, Cancer Res. 2004).

References:

- Kramer G, *et.al.*, (2004) Differentiation between Cell Death Modes using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18. *Cancer Research* 64: 1751-1756.
- Linder S, *et.al.*, (2004) Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. *Cancer Lett.* 214, 1-9.
- Kramer G, *et.al.*, (2006) Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. *Br J Cancer* 94: 1592-8.
- Cummings J, *et.al.*, (2007) Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. *Cancer Chemother Pharmacol* 60(6):921-4.
- Olofsson M, *et al.*, (2007) Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. *Clin Cancer Res.* 13: 3198-3206.

For further information please contact / Für weitere Informationen wenden Sie sich bitte an /
Pour plus d'informations, veuillez contacter:

www.tecomedical.com



A EUROBIO SCIENTIFIC COMPANY

Switzerland / Headquarters

TECO medical AG
Gewerbestrasse 10
4450 Sissach
Phone +41 61 985 81 00
Fax +41 61 985 81 09
Mail info@tecomedical.com

Germany

TECO medical GmbH
Wasserbreite 57
32257 Bünde
Phone +49 52 23 985 99 99
Fax +49 52 23 985 99 98
Mail info@tecomedical.com

Benelux

TECO medical Benelux BV
Prins Willem-Alexanderlaan 301
7311 SW Apeldoorn, The Netherlands
Phone +31 30 307 87 30
Fax +31 30 307 49 39
Mail benelux@tecomedical.com

Austria

TECO medical AG
Phone 0800 20 40 66
Fax 0800 20 40 55
Mail info@tecomedical.com